医療薬学
Online ISSN : 1882-1499
Print ISSN : 1346-342X
ISSN-L : 1346-342X
一般論文
抗がん剤連日投与時の制吐療法の実態調査と評価
兒玉 幸修寺田 智祐高橋 一栄矢野 育子乾 賢一
著者情報
ジャーナル フリー

2009 年 35 巻 9 号 p. 609-614

詳細
抄録

It has been reported that antiemetic therapy based on the guidelines produced by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) is effective in reducing emetic risk.However,while the effect of antiemetic therapy has been much reported for the intermittent administration of anticancer drugs,there have been few reports on such therapy in the case of the daily administration of anticancer drugs.In the present study,we investigated antiemetic therapy used for the prevention of nausea and vomiting induced by the daily administration of ICE combination chemotherapy (ifosphamide,carboplatin,and etoposide : ICE group) or DeVIC combination chemotherapy (dexamethasone,etoposide,ifosphamide,and carboplatin : DeVIC group) in 30 eligible patients.All patients received 5-HT3 serotonin receptor antagonists prophylactically during the daily administration of both types of chemotherapy but no patient received such prophylactic therapy after the administration of the anticancer drugs.The incidences of nausea and vomiting during chemotherapy for the ICE group (60.0% and 46.7%,respectively) were significantly higher than that in the DeVIC group (6.7% and 0%,respectively) but the incidences were comparable in the ICE (60.0% and 26.7%,respectively) and DeVIC groups (40.0% and 13.3%,respectively) following chemotherapy.These results suggested that dexamethasone could be administered prophylactically during the daily administration of anticancer drugs and its administration should be continued for a few days after the administration of anticancer drugs.

著者関連情報
© 2009 日本医療薬学会
次の記事
feedback
Top